Acarbose, Postprandial Hypotension and Type 2 Diabetes
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Postprandial hypotension carries a risk of significant morbidity and morbidity including
syncope, falls, dizziness, fatigue, stroke and myocardial infarction. Current therapy
consists of dietary manipulation (smaller meals) caffeine and octreotide injections all of
which are suboptimal and poorly studied.
The study hypothesis is that administration of Acarbose will decrease the drop in blood
pressure and increase in heart rate in response to food in people with Type 2 diabetes.
Acarbose suppresses postprandial glycemia be slowing digestion in the small intestine and
delaying gastric emptying.
This is a placebo-controlled cross over study involving 2 - 4 hour Meal Tests. During the
meal tests heart rate, blood pressure, cerebral artery velocity will be measured. During one
meal test subjects will receive Acarbose 50 mg po and during the other will receive placebo.
Order of treatment assignment will be done in randomized fashion. A total of approximately
200 cc of blood will be drawn during each meal test.